Earlier, Accurate Detection of Mesothelioma with New Testing?
According to a new report, pathologists from France and Canada believe they have been able to identify two test that would help distinguish between malignant mesothelioma and a benign growth on the mesothelial membrane. If these tests do work, it could mean for earlier and more accurate detection of mesothelioma in patients.
Because symptoms of mesothelioma are often similar to other diseases, it may be difficult to diagnose mesothelioma. However, it’s important for doctors to diagnose mesothelioma as quickly as possible so they can provide the necessary treatment to help increase the patient’s chance of survival. The two molecular tests identified by pathology researchers can help in providing a fix to this.
The first test uses gene testing to diagnose mesothelioma. It measures the level of p16 in the patient. This is a tumor suppressor protein which is often eliminated in mesothelioma patients. The testing — called fluorescence in situ hybridization (FISH) — makes it so doctors can detect the deletion of p16. According to the study of FISH testing, they found that none of the patients who had benign mesothelial tumors tested positive for p16 deletion.
The other test reviewed used immunohistochemical testing for BAP1 loss which is a common occurrence in patients with mesothelioma. If these tests can prove to be valuable in diagnosing mesothelioma, it can help doctors better treat mesothelioma patients sooner.
At Worthington & Caron, we are dedicated to helping mesothelioma patients in any way possible. This means we are advocates for clients in litigation and for mesothelioma research. If you have been diagnosed with mesothelioma, we can help you find the cause and take action on your behalf. Call us today to discuss your potential claim and learn what our firm can do to help you. We also have an extensive network of some of the top mesothelioma doctors in the country.
